Spectral awaits broader cardiac patent:
This article was originally published in Clinica
The US Patent Office says it will issue a new, broader cardiac panel testing patent to Spectral Diagnostics. Spectral's original 1994 patent covered panel tests using myoglobin, myosin light-chains and either CK-MB, troponin-I or troponin-T, in chest pain patients. The new patent will extend the range of analyte combinations and be independent of test format. New analytes include glycogen phosphorylase, fatty acid binding proteins and carbonic anhydrase, among others.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.